Omniscient, an artificial intelligence company developing advanced brain mapping technology, has raised $27.2 million (AU$41.1 million) in Series D funding to accelerate commercialization of its AI-driven brain analysis platform and expand its global healthcare footprint. The funding will support the continued growth of the company’s Quicktome® platform, development of new clinical applications, and expansion into emerging areas including brain-computer interfaces, stroke care, and movement disorders.

The Series D round was co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation, with continued support from existing investors including Gina Rinehart and Will Vicars. The financing builds on Omniscient’s previous capital raises and brings the company’s total funding to more than $70 million. The investment reflects growing interest in artificial intelligence technologies that can transform neurological diagnosis, treatment planning, and personalized medicine.

Founded in Australia, Omniscient is focused on using artificial intelligence to decode the complex networks of the human brain. The company’s technology uses connectomics, a field dedicated to mapping the brain’s intricate connections, to analyze individual brain structures and functions. Through AI-powered processing of medical imaging data, Omniscient aims to provide clinicians with detailed insights that can support more personalized approaches to neurological care.

The company’s flagship platform, Quicktome®, transforms standard MRI scans into detailed maps of an individual’s brain networks. These maps are designed to help physicians better understand brain connectivity and support decision-making in areas such as neurosurgery, epilepsy treatment, stroke management, and other neurological conditions. By providing clinicians with patient-specific brain information, Omniscient aims to improve precision in diagnosis and treatment planning.

The latest funding comes as healthcare systems increasingly adopt artificial intelligence to improve clinical workflows and enhance patient outcomes. Neurology remains one of the most challenging areas of medicine because of the complexity of the human brain and the difficulty of translating imaging data into actionable clinical insights. Omniscient’s technology seeks to address this challenge by combining neuroscience, medical imaging, and machine learning.

The company plans to use the new capital to expand commercialization efforts for Quicktome® and strengthen adoption among healthcare providers worldwide. Funding will also support continued research and development as Omniscient expands its technology into additional neurological applications. The company has identified opportunities in areas such as brain-computer interfaces, movement disorders, and stroke care, where improved understanding of brain connectivity could lead to better treatment strategies.

Omniscient has already achieved regulatory milestones for its technology, including FDA clearances for its products. These approvals have helped the company advance from research and development into commercial healthcare applications. By making advanced brain mapping available to clinicians, Omniscient aims to support a new generation of precision medicine focused on understanding each patient’s unique neurological profile.

Investor backing from OIF Ventures and the Australian National Reconstruction Fund Corporation highlights increasing confidence in Australia’s artificial intelligence and medical technology sectors. The participation of long-term supporters such as Gina Rinehart and Will Vicars further demonstrates continued investor commitment to Omniscient’s vision of applying AI to one of healthcare’s most complex challenges.

The company previously raised additional capital through earlier funding rounds, including a Series C round that supported product development and expansion into international markets. These investments helped Omniscient advance its AI-powered brain analysis platform and establish partnerships with healthcare organizations seeking innovative neurological solutions.

As artificial intelligence continues to reshape healthcare, companies developing specialized medical AI platforms are attracting increased attention from investors and clinicians. Unlike general-purpose AI systems, medical AI technologies must meet strict requirements for accuracy, reliability, and clinical usefulness. Omniscient’s approach combines advanced algorithms with neuroscience expertise to create tools designed specifically for healthcare professionals.

With its latest Series D financing, Omniscient is positioned to accelerate the global deployment of its brain mapping technology and expand its role in AI-enabled neurological care. Supported by OIF Ventures, the Australian National Reconstruction Fund Corporation, Gina Rinehart, and Will Vicars, the company aims to advance personalized brain healthcare by providing clinicians with deeper insights into the structure and function of the human brain.

Related Articles